Total Payments
$272,146
2022 Payments
$6,690
Companies
24
Transactions
240
Medicare Patients
481
Medicare Billing
$65,187
Payment Breakdown by Category
Consulting$181,625 (66.7%)
Other$53,286 (19.6%)
Travel$25,733 (9.5%)
Food & Beverage$5,154 (1.9%)
Research$4,842 (1.8%)
Education$1,506 (0.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $181,625 | 71 | 66.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $35,536 | 8 | 13.1% |
| Travel and Lodging | $25,733 | 68 | 9.5% |
| Compensation for serving as faculty or as a speaker for an accredited or certified continuing education program | $12,000 | 4 | 4.4% |
| Honoraria | $5,750 | 1 | 2.1% |
| Food and Beverage | $5,154 | 82 | 1.9% |
| Unspecified | $4,842 | 4 | 1.8% |
| Education | $1,506 | 2 | 0.6% |
Payments by Type
General
$267,303
236 transactions
Research
$4,842
4 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $71,741 | 60 | $0 (2021) |
| E.R. Squibb & Sons, L.L.C. | $31,882 | 40 | $0 (2022) |
| Merck Sharp & Dohme Corporation | $30,198 | 25 | $0 (2021) |
| Genentech USA, Inc. | $24,926 | 28 | $0 (2020) |
| Takeda Pharmaceuticals U.S.A., Inc. | $21,764 | 16 | $0 (2021) |
| Celgene Corporation | $15,320 | 18 | $0 (2018) |
| Amgen Inc. | $14,166 | 6 | $0 (2022) |
| Novartis Pharmaceuticals Corporation | $12,672 | 6 | $0 (2020) |
| AstraZeneca UK Limited | $11,505 | 10 | $0 (2019) |
| Daiichi Sankyo Inc. | $8,503 | 3 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2022 | $6,690 | 2 | Amgen Inc. ($6,490) |
| 2021 | $37,933 | 22 | AstraZeneca Pharmaceuticals LP ($9,990) |
| 2020 | $47,192 | 29 | Takeda Pharmaceuticals U.S.A., Inc. ($9,313) |
| 2019 | $55,514 | 51 | AstraZeneca Pharmaceuticals LP ($23,615) |
| 2018 | $62,941 | 78 | AstraZeneca Pharmaceuticals LP ($18,996) |
| 2017 | $61,875 | 58 | AstraZeneca Pharmaceuticals LP ($19,140) |
All Payment Transactions
240 individual payment records from CMS Open Payments — Page 1 of 10
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/12/2022 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $200.00 | General |
| 01/28/2022 | Amgen Inc. | LUMAKRAS (Drug) | Consulting Fee | Cash or cash equivalent | $6,490.00 | General |
| Category: Oncology | ||||||
| 11/19/2021 | Amgen Inc. | LUMAKRAS (Drug) | — | In-kind items and services | $3,045.16 | Research |
| Study: Clinical Validation of Guardant360 CDx as a Blood-Based Companion Diagnostic for Sotorasib • Category: Oncology | ||||||
| 07/30/2021 | Amgen Inc. | LUMAKRAS (Drug) | Consulting Fee | Cash or cash equivalent | $2,596.00 | General |
| Category: Oncology | ||||||
| 07/07/2021 | Merck Sharp & Dohme Corporation | — | Consulting Fee | Cash or cash equivalent | $1,500.00 | General |
| 06/04/2021 | Amgen Inc. | LUMAKRAS (Drug) | — | In-kind items and services | $62.58 | Research |
| Study: Clinical validation of plasma cell-free DNA sequencing in the phase 2 trial of sotorasib in patient • Category: Oncology | ||||||
| 06/03/2021 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $4,440.00 | General |
| 06/02/2021 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $2,220.00 | General |
| 05/21/2021 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Consulting Fee | Cash or cash equivalent | $525.00 | General |
| Category: ONCOLOGY | ||||||
| 05/21/2021 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Consulting Fee | Cash or cash equivalent | $525.00 | General |
| Category: ONCOLOGY | ||||||
| 05/19/2021 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $1,400.00 | General |
| 04/04/2021 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Consulting Fee | Cash or cash equivalent | $555.00 | General |
| Category: Oncology | ||||||
| 03/31/2021 | Janssen Biotech, Inc. | — | Consulting Fee | Cash or cash equivalent | $3,090.00 | General |
| 03/25/2021 | Janssen Scientific Affairs, LLC | — | Consulting Fee | Cash or cash equivalent | $1,010.00 | General |
| 03/25/2021 | Janssen Scientific Affairs, LLC | — | Consulting Fee | Cash or cash equivalent | $1,010.00 | General |
| 03/25/2021 | Janssen Scientific Affairs, LLC | — | Consulting Fee | Cash or cash equivalent | $1,010.00 | General |
| 03/25/2021 | Janssen Scientific Affairs, LLC | — | Consulting Fee | Cash or cash equivalent | $1,010.00 | General |
| 03/24/2021 | Ipsen Biopharmaceuticals, Inc | ONIVYDE (Drug) | Education | Cash or cash equivalent | $1,500.00 | General |
| Category: Oncology | ||||||
| 03/05/2021 | Daiichi Sankyo Inc. | — | Consulting Fee | Cash or cash equivalent | $2,031.25 | General |
| 03/05/2021 | Daiichi Sankyo Inc. | — | Consulting Fee | Cash or cash equivalent | $2,031.25 | General |
| 02/17/2021 | Takeda Pharmaceuticals U.S.A., Inc. | EXKIVITY (Drug) | Consulting Fee | Cash or cash equivalent | $3,000.00 | General |
| Category: ONCOLOGY | ||||||
| 02/17/2021 | Amgen Inc. | LUMAKRAS (Drug) | Consulting Fee | Cash or cash equivalent | $1,947.00 | General |
| Category: Oncology | ||||||
| 01/19/2021 | Boehringer Ingelheim Pharmaceuticals, Inc. | GILOTRIF (Drug) | Consulting Fee | Cash or cash equivalent | $650.00 | General |
| Category: ONCOLOGY | ||||||
| 01/09/2021 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Consulting Fee | Cash or cash equivalent | $2,775.00 | General |
| Category: Oncology | ||||||
| 12/02/2020 | Novartis Pharmaceuticals Corporation | MEKINIST (Drug), TABRECTA, TAFINLAR | Consulting Fee | Cash or cash equivalent | $3,750.00 | General |
| Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Clinical Validation of Guardant360 CDx as a Blood-Based Companion Diagnostic for Sotorasib | Amgen Inc. | $3,045 | 1 |
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $1,735 | 2 |
| Clinical validation of plasma cell-free DNA sequencing in the phase 2 trial of sotorasib in patient | Amgen Inc. | $62.58 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2021 | 3 | 177 | 266 | $54,020 | $29,180 |
| 2020 | 6 | 304 | 456 | $90,372 | $36,007 |
Total Patients
481
Total Services
722
Medicare Billing
$65,187
Procedure Codes
11
All Medicare Procedures & Services
11 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 86 | 156 | $34,320 | $18,721 | 54.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 71 | 90 | $12,600 | $7,297 | 57.9% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 20 | 20 | $7,100 | $3,162 | 44.5% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 112 | 205 | $45,345 | $16,929 | 37.3% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 78 | 111 | $16,040 | $7,332 | 45.7% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 35 | 35 | $12,425 | $5,120 | 41.2% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 13 | 29 | $5,179 | $2,591 | 50.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 18 | 20 | $5,210 | $1,828 | 35.1% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Facility | 2020 | 17 | 20 | $2,580 | $892.40 | 34.6% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2020 | 12 | 12 | $2,921 | $773.61 | 26.5% |
| 99441 | Physician telephone patient service, 5-10 minutes of medical discussion | Facility | 2020 | 19 | 24 | $672.00 | $540.96 | 80.5% |
About Dr. Joshua Bauml, MD
Dr. Joshua Bauml, MD is a Internal Medicine healthcare provider based in Philadelphia, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/07/2008. The National Provider Identifier (NPI) number assigned to this provider is 1740449487.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Joshua Bauml, MD has received a total of $272,146 in payments from pharmaceutical and medical device companies, with $6,690 received in 2022. These payments were reported across 240 transactions from 24 companies. The most common payment nature is "Consulting Fee" ($181,625).
As a Medicare-enrolled provider, Bauml has provided services to 481 Medicare beneficiaries, totaling 722 services with total Medicare billing of $65,187. Data is available for 2 years (2020–2021), covering 11 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Medical Oncology
- Location Philadelphia, PA
- Active Since 06/07/2008
- Last Updated 08/22/2019
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1740449487
Products in Payments
- TAGRISSO (Drug) $46,091
- IMFINZI (Drug) $27,771
- LUMAKRAS (Drug) $14,141
- ALUNBRIG (Drug) $11,851
- Alecensa (Biological) $11,498
- OPDIVO (Biological) $7,955
- MEKINIST (Drug) $7,500
- Non-Covered Product (Drug) $6,429
- Avastin (Biological) $6,258
- Abraxane (Drug) $4,747
- Enhertu (Drug) $4,440
- PD-L1 (Device) $3,866
- LIBTAYO (Biological) $3,150
- TABRECTA (Drug) $3,125
- EXKIVITY (Drug) $3,000
- Vitrakvi (Drug) $2,280
- FOUNDATIONONE CDX (Device) $1,750
- TAFINLAR (Drug) $1,735
- ONIVYDE (Drug) $1,500
- GILOTRIF (Drug) $1,300
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Philadelphia
Pitamber Devgon, Md, MD
Internal Medicine — Payments: $7.5M
Internal Medicine $7.5M
Dr. David Horn, M.d, M.D
Internal Medicine — Payments: $1.7M
Internal Medicine $1.7M
Daniel Rader, Md, MD
Internal Medicine — Payments: $1.6M
Internal Medicine $1.6M
Corey Langer, Md, MD
Internal Medicine — Payments: $742,647
Internal Medicine $742,647
Dr. Intekhab Ahmed, M.d, M.D
Internal Medicine — Payments: $621,997
Internal Medicine $621,997
David Goldmann, Md, MD
Internal Medicine — Payments: $587,696
Internal Medicine $587,696